BioTwin is being validated to provide clinicians with a longitudinal decision-support layer that monitors biological signals, identifies meaningful deviations from personal baselines, and flags structured risk signals across 5 clinical domains and 15 health conditions.
BioTwin is designed to augment clinical judgment. All flagged risk signals are routed to the treating physician for review, validation, and follow-up action.
Clinical authority remains fully with the physician. BioTwin provides structured risk summaries and longitudinal monitoring signals to support clinical triage and follow-up decisions.
BioTwin's models are grounded in peer-reviewed biomarker research and established clinical literature, with validation underway in clinical pilots.
Our platform serves hospitals, clinics, and their patients across multiple clinical workflows.
Multi-domain risk stratification across oncology, neurology, cardiology, lifestyle medicine, and life & health span, supported by low-friction at-home sample collection.
Track patient trajectories over time using repeat measurements, trend analysis, and longitudinal drift detection across monitored clinical areas.
Through TwinMe, patients access their longitudinal health view, follow changes over time, and remain connected to their care team between visits.
Risk-stratify patient populations, identify individuals requiring closer follow-up, and support more efficient resource allocation.
Healthspan and wellbeing optimization programs built on longitudinal multi-system monitoring and personalized trajectory tracking.
5 clinical domains. 15 health conditions.
BioTwin protocol aims to monitor biological signals, screen for meaningful deviations from each individual's baseline, and flag risk supporting clinical, triage and routing decisions. BioTwin does not replace physicians. BioTwin aims to provide a longitudinal decision-support research layer that strengthens primary-care workflows and reduces uncertainty, latency and diagnostic burden.
Flags early biological risk signals to support imaging and referral prioritization.
Multi-Cancer Early Detection (MCED)Helps flag early biological risk, including where no screening exists
Helps refine imaging, biopsy, and referral prioritization
Helps support surveillance and recurrence monitoring decisions
Supports earlier specialist triage before overt symptoms appear.
Helps identify early biological risk before overt symptoms
Helps support specialist referral and diagnostic triage pathways
Helps monitor progression and treatment response longitudinally
Highlights elevated cardiac risk for faster follow-up and intervention planning.
Helps flag elevated risk before acute events or decompensation
Helps support referral, imaging, and therapy optimization decisions
Helps monitor biological response to treatment over time
Tracks hidden metabolic decline and personalizes lifestyle action.
Track hidden metabolic and performance decline early
Personalize intervention intensity before complications emerge
Track whether lifestyle and therapy changes actually work
Transforms biological drift into proactive healthspan decisions.
Extends healthspan through continuous trajectory optimization
Detects early multi-system decline before disease onset
Converts biological drift into proactive healthspan action
Clinical decision-support research tool — not a diagnostic replacement. Currently in validation phase.
BioTwin is being validated through clinical research and pilot collaborations and is designed as a clinical decision-support layer under applicable regulatory frameworks. It provides structured decision support, not automated diagnosis. All outputs require review and validation by a licensed healthcare professional.
Built for healthcare compliance from day one. Our infrastructure meets the highest standards of data security and privacy, with granular consent management and privacy-by-design architecture.
Our biomarker models reference peer-reviewed clinical literature. Risk scores include confidence intervals and uncertainty quantification. We are transparent about validation status at every stage.
Prepare for 2027 pilot deployment. BioTwin aims to manage infrastructure and monitoring while clinicians retain full oversight. Limited onboarding slots for primary-care partners.